Head & Neck Cancer

LYT-200 is currently being investigated for those with solid tumors and hematologic malignancies.

Patients with factors such as lymphovascular space invasion or positive glossectomy specimen margins may be considered for adjuvant radiotherapy to optimize disease control of tongue squamous cell carcinoma.

The use of postoperative adjuvant radiation therapy led to less weight loss in patients with HPV-positive oropharynx cancer, according to Wade L. Thorstad, MD.

Frontline pembrolizumab with or without chemotherapy appears to remain a standard of care for patients with recurrent or metastatic head and neck squamous cell carcinoma based on data from the LEAP-010 study.

The FDA grants clearance to an oral immobilization stent designed to redirect radiation to the target tumor area for patients with head and neck cancer.

Study shows a high prevalence of thyroid cancer in transgender female patients.

Data from the phase 3 JUPITER-02 study and phase 2 POLARIS-02 study support the FDA approval of toripalimab-tpzi alone and in combination with gemcitabine and cisplatin in nasopharyngeal carcinoma.

Findings from a phase 2 trial also show that there is no progression-free survival or overall survival benefit with lapatinib plus chemoradiotherapy in patients with non-human papillomavirus–related head and neck cancer.

A yoga intervention program in patients with head and neck cancer appears to correlate with significantly fewer feeding tube placements compared with those receiving usual care.

Sacituzumab govitecan showed anti-tumor activity in patients with pretreated metastatic or locally recurrent head and neck squamous cell carcinoma.

Investigators will assess the safety and pharmacodynamics of ALE.C04 in patients with CLDN1-positive head and neck squamous cell carcinoma as part of a phase 1/2 clinical trial.

The FDA requires data from an additional clinical trial to support the potential approval of avasopasem for managing radiation-induced severe oral mucositis in patients with head and neck cancer.

How treatment paradigms regarding HPV-positive squamous cell carcinoma will evolve, particularly in the era of precision medicine, is a provocative question and is the subject of this review.

Sintilimab plus chemoradiotherapy produces a higher 3-year distant metastasis-free survival rate vs chemoradiotherapy alone among patients with advanced nasopharyngeal carcinoma in the phase 3 CONTINUUM trial.

Treatment with eftilagimod alpha in combination with pembrolizumab appears safe and well tolerated among patients with metastatic head and neck squamous cell carcinoma in the phase 2 TACTI-002 study.

With no standard treatment available, darolutamide shows potential activity among patients with androgen receptor–positive salivary gland cancer in the phase 2 DISCOVARY trial.

Investigators say that among those with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma who responded to nivolumab plus ipilimumab duration of response was not reached.

In addition to granting fast track designation to RRx-001, the FDA accepts an investigational new drug application for the agent to reduce and/or prevent radiation- and chemotherapy-associated oral mucositis.

Adding avelumab to VEGFR inhibitor axitinib may prolong survival and improve outcomes among patients with recurrent/metastatic adenoid cystic carcinoma.

Human papillomavirus and p16 discordance may correlate with a worse prognosis for oropharyngeal cancer, according to data from an individual patient data analysis.

Camrelizumab plus apatinib demonstrates impressive anti-tumor activity in a pretreated population with recurrent or metastatic nasopharyngeal carcinoma, although further research is needed, according to an expert from Memorial Sloan Kettering Cancer Center.

Data from the phase 3 ROMAN trial and the phase 2b GT-201 trial support the new drug application for avasopasem in radiotherapy-induced severe oral mucositis for those with head and neck cancer.

Findings from a randomized clinical trial suggest that tele-cognitive behavioral therapy may help reduce body image distress among survivors of head and neck cancer.

The biologic license application for toripalimab plus chemotherapy for the treatment of recurrent or metastatic nasopharyngeal carcinoma is expected to be resubmitted by mid-summer 2023.

The new drug application for avasopasem for radiotherapy-induced severe oral mucositis in patients with head and neck cancer is supported by findings from the phase 3 ROMAN trial and phase 2b GT-201 trial.

Adjuvant capecitabine following concurrent chemoradiotherapy yielded higher failure-free survival rates compared with chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.

Induction chemotherapy combined with concurrent lobaplatin chemoradiotherapy improved safety outcomes without sacrificing efficacy vs a cisplatin-based regimen in patients with head and neck squamous cell carcinoma.

Results from the phase 2 NRG-HN004 trial found durvalumab plus radiotherapy did not show improved progression-free survival vs cetuximab in patients with locoregionally advanced head and neck cancer who had a contraindication to cisplatin.

Findings from a retrospective cohort study found that immune checkpoint inhibitors induced promising responses in the first- and second-line treatment of head and neck squamous cell carcinoma.

Findings from the phase 3 KEYNOTE-048 study indicated that long-lasting improved survival benefit can be achieved with pembrolizumab plus chemotherapy compared with cetuximab and chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.